OptiNose, Inc. (OPTN) financial statements (2020 and earlier)

Company profile

Business Address 1020 STONY HILL ROAD
YARDLEY, PA 19067
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments147201235
Cash and cash equivalents147201235
Receivables1400
Inventory, net of allowances, customer advances and progress billings372
Inventory372
Other current assets421
Other undisclosed current assets02 
Total current assets:168213238
Noncurrent Assets
Property, plant and equipment343
Other noncurrent assets200
Total noncurrent assets:543
TOTAL ASSETS:173217241
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities352615
Accounts payable476
Accrued liabilities31189
Deferred revenue and credits0
Contract with customer, liability0
Other liabilities1  
Total current liabilities:362615
Noncurrent Liabilities
Long-term debt and lease obligation757372
Long-term debt, excluding current maturities757372
Operating lease, liability0
Other undisclosed noncurrent liabilities 0 
Total noncurrent liabilities:757372
Total liabilities:1119887
Stockholders' equity
Stockholders' equity attributable to parent62119154
Common stock000
Additional paid in capital490437366
Accumulated other comprehensive loss(0)(0)(0)
Accumulated deficit(428)(318)(211)
Total stockholders' equity:62119154
TOTAL LIABILITIES AND EQUITY:173217241

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Revenues3570
Revenue, net0
Cost of revenue
(Cost of Goods and Services Sold)
(5)(2) 
Gross profit:2950
Operating expenses(125)(106)(49)
Other undisclosed operating loss  (0)
Operating loss:(96)(100)(49)
Nonoperating income220
Investment income, nonoperating220
Foreign currency transaction gain (loss), before tax(0)(0)0
Interest and debt expense(17)(9)(1)
Other undisclosed income from continuing operations before equity method investments, income taxes 00
Net loss attributable to parent:(110)(107)(49)
Preferred stock dividends and other adjustments  (13)
Net loss available to common stockholders, diluted:(110)(107)(62)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
Net loss:(110)(107)(49)
Comprehensive loss:(110)(107)(49)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)
Comprehensive loss, net of tax, attributable to parent:(110)(107)(49)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: